

Afghanistan

COUNTRY GENERAL INFORMATION

Total population:	36 296 111
Gender F/M (%):	48.6 / 51.4
Population, age group <15 / ≥ 15 years (%):	44 / 56
Life expectancy at birth (F/M, years):	62 / 61
GDP (PPP int \$):	1935
Income status:	Low income
Number of 2 nd sub-national administrative level divisions, name:	399, District



EPIDEMIOLOGY

	VL	ACL	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	14	26 663	5402	N/A
Number of relapses: ¹	No data	1623	42	N/A
Total number of cases:	14	28 286	5444	N/A
Imported cases (#, %):	No data	No data	No data	No data
Gender distribution (% F):	21	53	48	N/A
Age group distribution (% , <5 / 5-14 / >14):	50 / 0 / 0	36 / 0 / 64	57 / 0 / 0	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.03	11.11	39.08	N/A
Number of endemic 2 nd sub-national administrative level divisions:	34	309	15	N/A
Population at risk (% , # at risk / total population): ²	11% 4 045 289/ 36 296 111	66% 24 005 451/ 36 296 111	4% 1 382 155/ 36 296 111	N/A
Was there any outbreak?	No	Yes	No	N/A
Number of new foci: ³	No data	No data	No data	N/A



Monthly distribution of new cases (January-December)

2017	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	3	1	0	1	1	0	2	1	2	0	2	1
ACL	2124	2255	2542	2867	2343	1751	1742	1688	1646	2556	2366	2783
ZCL	215	80	76	50	27	18	21	44	341	1195	1774	1561

N/A not applicable; VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis



Number of new cases and Incidence rate/10 000 at the national level from 2002 to 2017




¹Relapse in this country is defined for CL as: "Poor response to local or systemic treatment during follow-up and the physician decides to start second course"

²Defined as "Number of people living in 2nd sub-national administrative level endemic areas"

³Defined as "In this reporting period, an area at the 2nd sub-national administrative level reporting cases for the first time ever"

Disease distribution of new VL, ACL and ZCL cases at District level per 10 000 population (2017)



CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	1968
Type of surveillance (CL / VL):	Vertical / Vertical
Is there a vector control programme?	No
Type of insecticide used for Indoor residual Spraying (IRS):	NA
Year latest national guidelines (CL / VL):	2004 / 2014
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	No / No
Is there a reservoir host control programme?	No
Number of leishmaniasis health facilities (CL / VL):	582 / No data

DIAGNOSIS

	VL	ACL	ZCL	MCL
Number of people screened actively for:	No data	No data	No data	N/A
Number of people screened passively for:	No data	No data	No data	N/A
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / total cases):	100% (14/14)	21% (5518/26 663)	4% (219/5402)	N/A
Proportion of positive slides (% , # slides + / total slides):	100% (14/14)	No data	No data	N/A
Cases diagnosed clinically (% , # clinical cases / total cases):	0% (0/14)	79% (21 145/26 663)	96%(5182/5402)	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? (CL / VL): Yes / Yes
- ▶ Antileishmanial medicines included in the National Medicine List: Meglumine antimoniate, Sodium stibogluconate (SSG)

INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	ACL	ZCL
Cases that completed treatment (% , # completed treatment / new cases):	No data	36% (9529/26 663)	19% (1024/5402)
Initial cure rate (% , # cases initially cured / new cases):	No data	No data	No data
Failure rate (% , # cases with treatment failure / new cases): ⁴	No data	No data	No data
Case fatality rate (% , # cases who died / new cases):	No data	No data	No data

VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis

⁴Failure in this country is defined for CL as: "A patient who is not cured at the end of second course of the treatment"